52 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
. François stated, “I am very excited about Allocetra’s™ novel approach, using a first-in-class innovative cell therapy to explore the treatment of patients
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
.
We believe the Company’s primary innovative immunotherapy, AllocetraTM, represents a paradigm shift in macrophage reprogramming, moving from
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
on inflammatory and autoimmune indications. The Company, since its inception, considered the inherent properties of AllocetraTM as an innovative
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
the Company’s primary innovative immunotherapy, AllocetraTM, represents a paradigm shift in macrophage reprogramming, moving from targeting a specific
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm
the Company’s primary innovative immunotherapy, AllocetraTM, represents a paradigm shift in macrophage reprogramming, moving from targeting a specific
6-K
EX-99.1
pzfwkp0v f4r2
31 May 23
Report of Foreign Private Issuer
8:09am
424B5
mb6j5y3 vrg45
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.2
xxpq d4ixva2xfi
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
g4u39l6wvljtfa
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.2
bc7rtkxhvvktuaqm
27 May 22
Condensed Consolidated Financial Statements
4:39pm
F-3
atfv9mzuaom p2vjovmu
29 Apr 22
Shelf registration (foreign)
8:14am
6-K
EX-99.2
5m6qhdewlzisv8 l6ow
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.2
61e 3nmzmvkkvxl
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
6-K
EX-99.2
qcj 7bva8apkax1k
28 May 21
Condensed Consolidated Financial Statements
4:33pm
6-K
EX-99.1
edcjlxeaiewee
22 Mar 21
Report of Foreign Private Issuer
8:02am
424B5
z7zrjon m6
10 Feb 21
Prospectus supplement for primary offering
5:22pm
424B5
fv7oik7wlm0c1
9 Feb 21
Prospectus supplement for primary offering
4:56pm